Domača stranBLUE • NASDAQ
add
bluebird bio Inc
3,73 $
Po zaprtju:(1,88 %)+0,070
3,80 $
Konec trgovanja: 13. mar., 19:20:23 GMT -4 · USD · NASDAQ · Izjava
Prejšnji trg. dan.
3,86 $
Dnevni razpon
3,67 $ - 3,85 $
Letni razpon
3,56 $ - 30,90 $
Tržna kapitalizacija
36,26 mio. USD
Povprečni obseg
449,09 tis.
Razm. P/E
-
Dividendna donosnost
-
Primarna borza
NASDAQ
V novicah
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (USD) | sep. 2024info | Sprememba L/L |
|---|---|---|
Prihodek | 10,61 mio. | −14,36 % |
Stroški poslovanja | 62,94 mio. | −36,60 % |
Čisti dohodek | −60,81 mio. | 30,29 % |
Čista dobičkovnost prihodkov | −573,01 | 18,60 % |
Earnings per share | −6,20 | 53,03 % |
EBITDA | −48,76 mio. | 44,96 % |
Efektivna davčna stopnja | 0,10 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (USD) | sep. 2024info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 70,65 mio. | −59,46 % |
Skupna sredstva | 465,06 mio. | −24,21 % |
Skupne obveznosti | 470,84 mio. | 20,40 % |
Celoten lastniški kapital | −5,79 mio. | — |
Shares outstanding | 9,72 mio. | — |
Razmerje P/B | −6,43 | — |
Donosnost sredstev | −31,73 % | — |
Donosnost kapitala | −39,19 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (USD) | sep. 2024info | Sprememba L/L |
|---|---|---|
Čisti dohodek | −60,81 mio. | 30,29 % |
Denar iz dejavnosti | −68,93 mio. | −37,72 % |
Denar iz naložb | 466,00 tis. | −99,25 % |
Denar iz financiranja | −6,10 mio. | 48,42 % |
Neto sprememba denarnih sredstev | −74,57 mio. | −38.339,49 % |
Prost denarni tok | −48,44 mio. | 22,76 % |
Vizitka
bluebird bio, Inc., based in Somerville, Massachusetts, is a biotechnology company that develops gene therapies for severe genetic disorders.
The company's only - in the European Union - approved drug is betibeglogene autotemcel, which treats transfusion-dependent beta thalassemia, a rare genetic blood disorder, and has been approved for use by the European Medicines Agency. The company has been criticized for the $1.8 million cost of the drug, which is the second most expensive drug in the world.
The company is developing LentiGlobin gene therapy for the treatment of sickle cell disease and cerebral adrenoleukodystrophy. It is also developing T cell product candidates to treat acute myeloid leukemia, Merkel-cell carcinoma, diffuse large B-cell lymphoma, and MAGEA4 solid tumors. Wikipedia
Generalni direktor
Datum ustanovitve
16. apr. 1992
Sedež organizacije
Spletno mesto
Zaposleni
282
